Hugel
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Hugel researches, manufactures, and supplies botulinum toxin products, the injectable treatments widely used to relax facial muscles and reduce wrinkles, as well as hyaluronic acid dermal fillers used for skin volume and contouring.
Its products reach patients through clinics and medical practitioners across dermatology, plastic surgery, neurology, ophthalmology, and several other specialties. Listed on KOSDAQ, Korea's tech and small-cap board, the company covers both of its main product lines, botulinum toxin and dermal fillers, through its own sales and marketing division as well as a key subsidiary focused on filler development and manufacturing.
Summary is AI-generated and may contain errors · figures from DART filings
A formerly separate sales entity, Hugel Pharma, was fully absorbed into Hugel, consolidating product distribution under one corporate structure.
Hugel in five facts
What does Hugel do?
Hugel researches, manufactures, and supplies botulinum toxin products, the injectable treatments widely used to relax facial muscles and reduce wrinkles, as well as hyaluronic acid dermal fillers used for skin volume and contouring.
Where is Hugel listed and in which sector?
Hugel (Korean name: 휴젤) trades under KRX code 145020 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Hugel?
Its market capitalisation was US$1.8B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Hugel's latest annual revenue and operating profit?
For fiscal year 2025, Hugel reported revenue of US$320.9M, operating profit of US$151.6M and net income of US$110.9M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 14.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meetingSep 30
- Report on securities held by executives/major shareholdersSep 30
- Investor relations (IR) meetingSep 14
- Report on securities held by executives/major shareholdersSep 9
- Investor relations (IR) meetingSep 7
- [quarterly, individual company] Large business group status disclosureAug 31
- Operating results (consolidated) (preliminary) (fair disclosure)
Hugel filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$97M (+25.1% year on year), operating profit of US$39.4M (−1.1% year on year) and net income of US$31.5M (+17.1% year on year).
Earnings · Aug 6 - Material event report (treasury share disposal)
Hugel disclosed a plan to sell treasury shares worth US$1.44M, about 0.1% of its market value.
Treasury Shares · Aug 6 - Share-pledge agreement that may change the largest shareholder
Hugel's largest shareholder (Aphrodite Acquisition Holdings LLC) pledged shares as loan collateral, securing up to US$502M.
Ownership change · Jun 17 - Share-pledge agreement tied to the largest shareholder terminated/cancelled
A previously disclosed share pledge on Hugel's largest shareholder (Aphrodite Acquisition Holdings LLC) was released or cancelled, freeing collateral of US$439M.
Ownership change · Jun 17 - Operating results (consolidated) (preliminary) (fair disclosure)
Hugel filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$80.2M (+29.9% year on year), operating profit of US$32.7M (+22.3% year on year) and net income of US$27.9M (+31.5% year on year).
Earnings · May 7 - Operating results (consolidated) (preliminary) (fair disclosure)
Hugel filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$81.9M (+21.3% year on year), operating profit of US$40.3M (+26.2% year on year) and net income of US$25.3M (−11% year on year).
Earnings · Feb 11